PDCD1 and neoplasm of esophagus: This observation of better functional performance status in the Japanese subpopulation compared with the global overall population of RATIONALE-302 is consistent with findings in other studies investigating anti-PD-1 antibodies as monotherapy in second-line treatment of advanced esophageal tumors, or in combination with chemotherapy or other immunotherapies in first-line treatment [10, 11, 18].